论文部分内容阅读
The thiazolidinedione class PPARγ agonists as antidiabetic agents are restricted in clinical use because of the side effects such as edema,weight gain and heart failure.The single and selective agonism of PPARγ is the main cause of these side effects.The multi-target cooperative PPARα/γ/δ pan agonist development is the hot topic in the antidiabetic medicinal chemistry field.In order to identify PPARα/γ/δ pan agonists,the compound database was established by core hopping of rosiglitazone,which was then docked into PPARα/γ/δ active site to screen out a number of candidates with higher docking score and better interaction with active site.Further ADMET prediction was done to give eight compounds.